TY  - GEN
AU  - Ebbinghaus,Scot
AU  - Rubin,Eric
AU  - Hersh,Evan
AU  - Cranmer,Lee D
AU  - Bonate,Peter L
AU  - Fram,Robert J
AU  - Jekunen,Antti
AU  - Weitman,Steve
AU  - Hammond,Lisa A
TI  - A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors
SN  - 1078-0432
PY  - 2006///0404
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Area Under Curve
KW  - Depsipeptides
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Infusions, Intravenous
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasms
KW  - Oligopeptides
KW  - Time Factors
KW  - Tomography, X-Ray Computed
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1158/1078-0432.CCR-05-0909
ER  -